Table 1 Baseline characteristics and microbiologic confirmation of tuberculosis in 209 HIV-1 infected and 83 HIV-1 uninfected patients receiving antituberculosis treatment
HIV-1 infected (n = 209) | HIV-1 uninfected (n = 83) | p-value | |
|---|---|---|---|
Female, n (%) | 112 (54) | 25 (30) | <0.001 |
Age in years, median (IQR) | 35 (30-41) | 38 (29-49) | 0.035 |
CD4 count at TB diagnosis, n (%): | |||
>350 cells/mm 3 | 36 (17) | - | |
200 - 350 cells/mm 3 | 37 (18) | - | |
< 200 cells/mm 3 | 133 (64) | - | |
Not performed | 3 (1) | - | |
Previous TB, n (%) | 71 (34) | 19 (23) | 0.070 |
TB diagnosed at referral hospital, n (%): | 79 (38) | 13 (16) | <0.001 |
Microbiologic confirmation at TB diagnosis 1 , n (%) | 123 (59) | 68 (82) | <0.001 |
Drug susceptibilities known at TB diagnosis 1 , n (%) | 67 (32) | 49 (59) | <0.001 |
Culture sent at TB diagnosis, n (%) | 169 (81) | 68 (82) | 1.000 |
Extra-pulmonary TB, n (%): | 82 (39) | 14 (17) | <0.001 |
Weight at TB diagnosis in kg, median (IQR) | 54 (49-62) | 54 (49-64) | 0.644 |
Microbiologic confirmation at TB diagnosis and during 24 weeks of follow-up 2 , n (%) | 153 (73) | 70 (84) | 0.048 |
Drug susceptibilities known at TB diagnosis and during 24 weeks of follow-up 2 , n (%) | 117 (56) | 57 (69) | 0.296 |
Culture sent at TB diagnosis and/or during 24 weeks of follow-up, n (%) | 190 (91) | 76 (92) | 1.000 |